Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of peresolimab in healthy participants
NCT03715192Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of peresolimab in rheumatoid arthritis (RA) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug. Started Dec 2018; status: completed.
02
Drugs
peresolimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03715192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03715192.